You are at goal weight or close enough to see it. There are three places you could ask what comes next. The physician your insurance pays for will not prescribe a GLP-1. A membership app writes the prescription. A telehealth clinician you may never have met on video signs it. GLP-1 maintenance with three providers means three partial records, three message threads and nobody whose job is the next year of your care.

This piece answers the question you are probably about to type. What happens after I reach my goal weight? The honest answer is that a decision happens. Your dose stays where it is, comes down or stops. Whoever makes that call should be reading your labs and should still be there next quarter to see how it went. GoodLife Health gives you that person: a clinician who manages the long haul of GLP-1 care, with labs before the prescription and every quarter after, for $299 a month in all 50 states.

We do not know what your maintenance plan should be. Nobody does until someone has read your numbers. What we can describe is what a good plan needs, why your current setup struggles to produce one and what it costs to put one person in charge.

Key Takeaways
  • Goal weight is the point where your dose stays, comes down or stops.
  • With three providers, each holds one slice of your record and none owns that decision.
  • The decision belongs with a clinician who reads your markers every quarter and earns nothing on the dose.
  • Zepbound's self-pay price on LillyDirect varies by dose, so a maintenance dose is also a cost decision.
  • GoodLife Health is $299 a month with four lab panels a year and medication billed by your own pharmacy.
  • Keep your insurance for the hospital. The membership replaces the primary-care relationship.

Three providers and nobody holding the plan

Start with what each of them does for you today. Your primary care physician is paid through the premium you send your insurer every month. The visit is short and the panel is basic. When you raised a GLP-1, the answer was no. That leaves the physician who holds your history with no part in the medication that is changing it.

The app is where the prescription lives. A questionnaire led to a starting dose. The emails since have been about the next refill and the next step up. The service is built around that prescription. It may never have asked for your blood work.

The telehealth signer is a licensed clinician whose name is on the order. A signature confirms that someone with a license approved the prescription. It does not give you a clinician who follows you from one quarter to the next.

Then there are the things nobody holds. Your last A1C, if it was ever drawn, sits in your insurer's portal. Your dose history sits in the app. The side effect you mentioned in your second month sits in a message thread with the signer. Your lipid panel may be a year old. Each provider is doing the job it was set up to do. None of them was set up for the job that begins at goal weight.

You are also paying for all three. The premium buys a visit that will not touch the medication. The app's fee buys the prescription. The medication carries its own bill. Each payment covers one piece of your care and no payment covers the coordination between them.

None of this is a failure on your part. When the in-network door closed, you found another one. The weight came off. That part of the work had an obvious owner in the app and the signer. The part that starts now has no owner at all.

Why goal weight is a decision nobody in your care owns

Weight loss on a GLP-1 has a simple shape. The dose starts low and rises in steps. The scale moves. At each step, the question has a fairly obvious answer. The system you are in is good at answering it.

Goal weight changes the question. Should the dose stay where it is? Should it come down to the lowest dose that holds your progress? Could it stop altogether? If it did, what would you want to watch and how often? These are clinical questions. They need someone who knows your history, has your current markers and will still be there in three months to see what the decision did.

Now hold your three providers up against those questions. The primary care physician has your history and no part in the drug. The app has the drug and the dose history. It may have no blood work at all. The signer has a license and no relationship with you. The question that matters most at goal weight falls between all three of them.

Incentives matter here too. As Cardiometabolic Optimization: The Definitive Guide explains, most telehealth platforms earn more when you are prescribed more through margin on the molecule or upcharges as the dose rises. That is a statement about business models. It says nothing about the people who work inside them. It does mean that nothing in your current setup is paid to suggest a lower dose. The same guide notes that when nobody profits from the prescription, deprescribing counts as a success whenever the labs support it.

The scale is also only one number. The markers that show whether your metabolism has changed are others: A1C, fasting insulin, ApoB and the lipid panel. A basic panel often stops at LDL and glucose. A labs-first practice draws ApoB as well and measures fasting insulin before glucose turns abnormal. A maintenance plan built on the scale alone is built on a fraction of the evidence. A plan set once and never checked again is a guess.

Clinical note

A GLP-1 or hormone protocol built without labs is a guess. Baseline metabolic and hormone panels should always precede protocol design.

Cost belongs in the same conversation. In September 2026, the manufacturers published their own self-pay prices. Through NovoCare, Wegovy pens are $199 a month for the first two fills (an introductory offer for new patients through December 2026) and $349 a month after. The Wegovy pill starts from $149 a month at lower doses. Through LillyDirect, Zepbound vials are $299 to $449 a month depending on dose. A branded medication's price from its maker is now published and dated. That means the dose a clinician settles on for maintenance is also a number you can read on a price list. It is one more reason the person deciding the dose should be reading your markers and earning nothing on the answer.

Insurance is a separate question. If your plan covers a GLP-1, that is between you, the plan and the pharmacy. Prior authorization is the pharmacy's process. Nobody can honestly promise coverage. We do not.

In your care today, nobody has the job that starts at goal weight.

What one clinician does with the years after goal weight

GoodLife Health is precision direct primary care for cardiometabolic optimization. One clinician manages the long haul of your GLP-1 care, with labs before the prescription and every quarter after. Here is how that answers the goal-weight question.

It begins with a test. Before a prescription is continued, changed or written, a clinician reads a full cardiometabolic panel. If you join near goal weight, that panel may be the first complete picture anyone has taken of you since the medication started. It shows where your A1C, fasting insulin, ApoB and lipids sit today. The maintenance decision then starts from evidence.

Next, the clinician reviews the dose you are on now and decides the next step with you. That may mean staying where you are. It may mean moving to the lowest dose that holds your progress. When your labs support it, it may mean stopping. The fee is the same whichever branded medication is indicated. Prescriptions are branded and FDA-approved: Wegovy, Zepbound, Mounjaro or Ozempic, with oral options when they are indicated. We do not prescribe compounded GLP-1. If your app has been sending one, the clinician will go through the branded options with you.

Then it repeats. The panel is drawn four times a year and every result is in your hands. Between visits, you message the care team. When a conversation needs a face, there is a video visit. The clinician stays, so the person reading your panel at month nine is the person who read it at month six. A dose lowered in one quarter is checked in the next.

Medication is prescribed to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on medication. The fee is the same whatever medication is indicated and whatever the dose. We call this Medication-Neutral Pricing. It is why a lower dose at goal weight costs us nothing to recommend.

Keep your insurance. The membership pairs with insurance for catastrophic coverage and does not replace it. What it replaces is the primary-care relationship for your cardiometabolic care. The app and the signer give way to one clinician who also holds the labs. Whether you keep seeing your in-network physician for other things is your decision. What Does a Direct Primary Care Membership Include in 2026 sets out where a membership ends and insurance begins.

The membership in numbers
$299
a month, month to month from month three
4
cardiometabolic lab panels a year
50
states where its clinicians are licensed
$3,588
the membership for a full year

The membership is $299 a month. At sign-up, $598 is held on your card to cover the first two months. It is a hold. It is charged only once the clinician accepts you into care. If the clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are charged and are non-refundable. From month three, the membership is month to month. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. Not everyone is accepted. The path is the eligibility check, the intake, the checkout and then a clinician's review.

What the fee buys is the quarterly panel, a clinician who stays, messaging with the care team and video visits. What it returns is the diagnosis a visit never produced, your markers followed from one quarter to the next and an end to the eight-minute visit. What makes it different is the order of things. We test first and treat second. We sell neither the drug nor the dose. We will not set our fee against a $99 app. The difference that matters at goal weight is who gets paid when the dose goes up. Here, nobody does.

If you are at goal weight or close to it, the next dose decision is near. It is easier to make well with a baseline panel already drawn than after another refill has gone out at the old dose.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

What to do this week, whether or not you join

Some of this is worth doing even if you never sign up with us.

  1. Put your dose history on one page: every dose, the date it started and who changed it.
  2. Ask your primary care office for your most recent A1C and lipid panel, with the dates they were drawn.
  3. Ask the app whether it has ever ordered blood work for you. If it has, get the results.
  4. Send the signer and the app the same written question. Who decides my dose at goal weight, on what evidence and when will it next be reviewed?
  5. If the medication you receive is compounded, read the FDA's page on unapproved GLP-1 drugs used for weight loss and ask your prescriber exactly what you are taking.
  6. Look up the manufacturers' dated self-pay prices for the branded options so you know what maintenance would cost at the pharmacy.

Then choose one person to own the goal-weight question. Give that person the page and the results. If one of your current three takes it on and follows it every quarter, you may not need us. That would be a good outcome.

Who this is not for

This membership is not for someone who wants a prescription and nothing more. If the lowest monthly fee for a refill is the whole goal, an app at $99 a month is built for that purpose and we are not. It is not for anyone who wants compounded GLP-1, because we prescribe branded, FDA-approved medication only. It is not for someone who needs a promise of a maintenance dose, a final weight or a date to stop. No clinician who reads labs can make that promise in advance. It does not replace your insurance or offer full-scope primary care for everything else in your life. It is also only for people living in the United States.

If you want one owner for the decision, the terms are short. The membership is $299 a month. At sign-up, $598 is held on your card for the first two months and is charged only once a clinician accepts you into care. If you are not accepted, the hold is released and you are never charged. Once you are accepted, the first two months are non-refundable. After them, the membership is month to month. It buys four lab panels a year and a clinician who stays. Your medication goes to your own pharmacy at its price with nothing taken on it. A baseline drawn now makes the next decision an informed one.

Related Reading

References

  1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
  2. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
  3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss